Allan Jordan

Allan Jordan is Senior Vice President of Oncology Drug Discovery at Sygnature Discovery, bringing more than 25 years of experience in medicinal chemistry and oncology drug discovery. He has an outstanding track record of advancing drug candidates from target validation through to clinical development, contributing to numerous programs across small molecules, molecular glues, protein degraders, and ADCs. Prior to joining Sygnature, he served as Head of Chemistry at the Cancer Research UK Manchester Institute Drug Discovery Unit. A recognized scientific leader and communicator, Allan combines deep expertise in oncology therapeutics with a passion for innovation, collaboration, and translating discovery science into patient benefit.